A 55-year-old man presented with a 3-week history of dry cough and left pleuritic chest pain with a new exudative pleural effusion. Sixteen years earlier, he was diagnosed with sarcoidosis presenting with hilar lymphadenopathy, erythema nodosum, mildly disturbed liver function tests and noncaseating granulomata on liver biopsy, with no evidence of pulmonary parenchymal disease. He was treated with prednisone and in recent years maintained at a low daily dose, until it was eventually discontinued two years prior to his present illness. There was no evidence of infection or malignancy, and the fluid resolved following treatment with naproxen. Three weeks later the patient presented with sudden onset of dyspnea and left chest pain. After starting intravenous heparin for suspected pulmonary emboli, the patient developed hemodynamic instability which was accompanied by abdominal tenderness and decreasing hematocrit. Splenic rupture was diagnosed, and the patient underwent splenectomy. Pathology specimens revealed a hemorrhagic infarct with subcapsular hematoma, and numerous noncaseating granulomata within the splenic tissue. This patient had recurrent sarcoidosis with two rare manifestations of the disease, 2 years after withdrawing low dose prednisone, given for a prolonged time. The possibility of reemergence of the disease in organs other than the organs involved in the initial presentation should always be considered in sarcoidosis.

Keywords:
Sarcoidosis, Splenic rupture, Pleural effusion, Prednisone
1.
Gottlieb JE, Israel HL, Steiner RM, et al: Outcome in sarcoidosis: The relationship of relapse to corticosteroid therapy. Chest 1997;111:623–631.
2.
Johns CJ, Schonfeld SA, Scott PP, et al: Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Ann NY Acad Sci 1986;465:702–712.
3.
Hunninghake GW, Gilbert S, Pueringer R, et al: Outcome of the treatment of sarcoidosis. Am J Respir Crit Care Med 1994;149:893–898.
4.
Johard U, Ekuland A: Recurrent Lofgren’s syndrome in three patients with sarcoidosis. Sarcoidosis 1993;10:125–127.
5.
Soskel NT, Sharma OP: Pleural effusion in sarcoidosis: Case presentation and detailed review of the literature. Semin Respir Dis 1992;13:492–514.
6.
Sharma OP, Gordson J: Pleural effusion in sarcoidosis: A report of six cases. Thorax 1975;30:95–101.
7.
Nicholls AJ, Friend JA, Legge JS: Sarcoid pleural effusion: Three cases and review of the literature. Thorax 1980;35:277–281.
8.
Fordice J, Katras T, Jackson RE, et al: Massive splenomegaly in sarcoidosis. South Med J 1992;85:775–778.
9.
Webb AK, Mitchell DN, Bradstreet CM, et al: Splenomegaly and splenectomy in sarcoidosis. J Clin Pathol 1979;32:1050–1053.
10.
Knodel AR, Beekman JF: Severe thrombocytopenia and sarcoidosis. JAMA 1980;243:258–259.
11.
Phillips AK, Luchette AA: Rupture of spleen due to sarcoidosis. Ohio Med J 1952;48:617–619.
12.
Sharma OP: Splenic rupture in sarcoidosis: Report of an unusual case. Am Rev Respir Dis 1967;96:101–102.
13.
James I, Wilson AJ: Spontaneous rupture of the spleen in sarcoidosis. Br J Surg 1946;33:280–282.
14.
Remy-Jardin M, Remy J, Deschildre F, et al: Diagnosis of pulmonary embolism with spiral CT: Comparison with pulmonary angiography and scintigraphy. Radiology 1996;200:699–706.
15.
van-Rossum AB, Pattynama PM, Tjin-Aton ER, et al: Pulmonary embolism: Validation of spiral CT angiography in 149 patients. Radiology 1996;201:467–470.
16.
Cross JJ, Kemp PM, Walsh CG, et al: A randomized trial of spiral CT and ventilation perfusion scintigraphy for the diagnosis of pulmonary embolism. Clin Radiol 1998;53:177–182.
17.
Mullins MD, Becker DM, Hagspiel KD, et al: The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism. Arch Intern Med 2000;160:293–298.
18.
Hansell DM: Spiral computed tomography and pulmonary embolism: Current state. Clin Radiol 1997;52:575–581.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.